StockNews.com upgraded shares of Immunic (NASDAQ:IMUX - Free Report) from a sell rating to a hold rating in a research report released on Wednesday.
Several other analysts have also recently issued reports on the stock. D. Boral Capital reissued a "buy" rating and set a $17.00 price target on shares of Immunic in a research report on Wednesday, February 26th. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $12.67.
Read Our Latest Analysis on IMUX
Immunic Trading Up 2.7 %
IMUX traded up $0.03 on Wednesday, hitting $1.15. The company had a trading volume of 534,219 shares, compared to its average volume of 924,680. The firm has a market cap of $103.59 million, a P/E ratio of -0.93 and a beta of 1.89. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11. The company's fifty day moving average price is $1.06 and its 200 day moving average price is $1.23.
Institutional Trading of Immunic
Large investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Immunic during the third quarter worth approximately $50,000. Invesco Ltd. purchased a new stake in shares of Immunic during the fourth quarter worth approximately $37,000. Jane Street Group LLC increased its stake in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after buying an additional 38,553 shares during the period. HB Wealth Management LLC purchased a new stake in shares of Immunic during the fourth quarter worth approximately $81,000. Finally, Barclays PLC purchased a new position in Immunic in the fourth quarter valued at approximately $84,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.
About Immunic
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Featured Stories
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
